Peptides
Medchemexpress LLC HY-18678A 50mg , Bremelanotide (Acetate) PT-141 Acetate CAS:1607799-13-2 Purity:98%
Medchemexpress, HY-18678A 50mg Bremelanotide (Acetate) PT-141 Acetate CAS:1607799-13-2 Formula:C52H72N14O12 Purity:98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.
Oxytocin, USP, Spectrum™ Chemical
O1360, 50-56-6, C43H66N12O12S2
Invitrogen™ Human RTN4RL2 Synthetic Peptide
Synthetic Peptide
Invitrogen™ Human PIWIL2 Synthetic Peptide
Synthetic Peptide
Medchemexpress LLC TAT-cyclo-CLLFVY | 1446322-66-2 | 98.8% | 2559.08 | 10 MG
TAT-cyclo-CLLFVY is a cyclic peptide inhibitor of HIF-1 heterodimerization, effectively inhibiting hypoxia signaling in cancer cells. It functions by disrupting the HIF-1α/HIF-1β protein-protein interaction. This product is for research use only.
- Disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM
- Inhibits HIF-1 activity in mammalian cell luciferase reporter assay with an IC50 of 19±2 μM
- Shows similar inhibition in MCF-7 breast cancer cells with an IC50 of 16±1 μM
- Features a molecular weight of 2559.08
- Has a chemical formula of C111H188N42O24S2
Medchemexpress LLC Tat-cyclo-cllfvy | 1446322-66-2 | 98.8% | 2559.08 | 1 MG
TAT-cyclo-CLLFVY is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. It disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM.
- Cyclic peptide inhibitor of HIF-1 heterodimerization
- Inhibits hypoxia signaling in cancer cells
- Disrupts HIF-1α/HIF-1β protein-protein interaction
- Inhibits HIF-1 activity in mammalian cell luciferase reporter assay
- Powder storage: -80°C for 2 years, -20°C for 1 year
- In solvent storage: -80°C for 6 months, -20°C for 1 month
Medchemexpress LLC TAT-cyclo-CLLFVY | 1446322-66-2 | 98.8% | 2559.08 | 5 MG
TAT-cyclo-CLLFVY is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. It disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM and inhibits HIF-1 activity in mammalian cell luciferase reporter assays with IC50 values of 19±2 μM (hypoxia) and 16±1 μΜ (MCF-7 breast cancer cells).
- Disrupts HIF-1α/HIF-1β protein-protein interaction
- Inhibits hypoxia signaling in cancer cells
- Inhibits HIF-1 activity in mammalian cell luciferase reporter assays
- For research use only
Carbosynth LLC. 2-Furoyl-Leu-Ile-Gly-Arg-Leu-Orn-NH2, 1mg, MW: 777.97, Molecular formula: C36H63N11O8, CAS# 729589-58-6
This item has a minimum order quantity of 2 per supplier requirements
Synonyms: 2-Furoyl-Leu-Ile-Gly-Arg-Leu-Orn-NH2; 2-Furoyl-LIGRLO-Amide, Application: Potent and Selective Protease-Activated Receptor 2 (PAR2) Agonist, Salt Form:, Acetate Salt, Storage Temperature: -20C, References: J.J. McGuire, M. Saifeddine, C.R. Triggle, K. Sun, and M.D. Hollenberg, J Pharmacol. Exp. Ther., 309, 1124 (2004)., N. Vergnolle, Br. J. Pharmacol., 141, 1264 (2004). (Review)
Carbosynth LLC. H-Ser-Leu-Ile-Gly-Arg-Leu-NH2, 1mg, MW: 656.83, Molecular formula: C29H56N10O7, CAS# 171436-38-7
This item has a minimum order quantity of 3 per supplier requirements
Synonyms: H-Ser-Leu-Ile-Gly-Arg-Leu-NH2, SLIGRL-Amide, Application: Protease-Activated Receptor 2 (PAR2) Agonist, Salt Form:, Acetate Salt, Storage Temperature: -20C, References: B. Al-Ani, M. Saifeddine, and M.D. Hollenberg, Can. J. of Physiol. Pharmacol., 73, 1203 (1995)., N. Vergnolle, Br. J. Pharmacol., 141, 1264 (2004). (Review)